TriangleNCT05140382 · OUTCOME
Duration of Response (DoR)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From Screening (Day -30 to Day-1) until disease progression or survival until death (26 months).
What was measured
Duration of response is defined as the time from the first objective response to the time of documented disease progression or death due to any cause, whichever occurs first.
Analysis population: Response evaluable set included all dosed participants who have measurable disease at baseline and had objective response.
Groups in this outcome
Cohort 1 Non-NK PTCL
Participants with non-NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.
Cohort 2 NK PTCL
Participants with NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.
Cohort 3 cHL
Participants with cHL received 12 mg dose of AZD4573 once weekly until disease progression.
| Group | Source count |
|---|---|
| Cohort 1 Non-NK PTCL | 7 |
| Cohort 2 NK PTCL | 0 |
| Cohort 3 cHL | 4 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Cohort 1 Non-NK PTCL | NA | Not reported | 1.8 | NA | The median and 95% CI were calculated with the Kaplan Meier process (a process in medical research to measure the proportion of participants surviving for a certain time after receiving treatment) and were non estimable as there was insufficient number of participants with the event of interest (less than 50%) occurred in the study. |
| Cohort 3 cHL | 5.2 | Not reported | 1.9 | NA | The 95% CI was calculated with the Kaplan Meier process (a process in medical research to measure the proportion of participants surviving for a certain time after receiving treatment) and was non estimable as there was insufficient number of participants with the event of interest (less than 50%) occurred in the study. |
Complete source fields
- classes
- categories
- measurements
- comment
- The median and 95% CI were calculated with the Kaplan Meier process (a process in medical research to measure the proportion of participants surviving for a certain time after receiving treatment) and were non estimable as there was insufficient number of participants with the event of interest (less than 50%) occurred in the study.
- group Id
- OG000
- lower Limit
- 1.8
- upper Limit
- NA
- value
- NA
- comment
- The 95% CI was calculated with the Kaplan Meier process (a process in medical research to measure the proportion of participants surviving for a certain time after receiving treatment) and was non estimable as there was insufficient number of participants with the event of interest (less than 50%) occurred in the study.
- group Id
- OG002
- lower Limit
- 1.9
- upper Limit
- NA
- value
- 5.2
- denoms
- counts
- group Id
- OG000
- value
- 7
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 4
- units
- Participants
- description
- Duration of response is defined as the time from the first objective response to the time of documented disease progression or death due to any cause, whichever occurs first.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants with non-NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.
- id
- OG000
- title
- Cohort 1 Non-NK PTCL
- description
- Participants with NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.
- id
- OG001
- title
- Cohort 2 NK PTCL
- description
- Participants with cHL received 12 mg dose of AZD4573 once weekly until disease progression.
- id
- OG002
- title
- Cohort 3 cHL
- param Type
- MEDIAN
- population Description
- Response evaluable set included all dosed participants who have measurable disease at baseline and had objective response.
- reporting Status
- POSTED
- time Frame
- From Screening (Day -30 to Day-1) until disease progression or survival until death (26 months).
- title
- Duration of Response (DoR)
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice